English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The quality of life (QOL) of persons affected by generalized anxiety disorder (GAD), a condition characterized by periods of excessive anxiety and worry (American Psychiatric Association 1994), is significantly impaired, with an established link between GAD and impairment in a variety of areas (Henning et al. 2007). GAD is associated with increased self-reported disability days and impairments in psychosocial functioning, role functioning, work productivity, and QOL (Massion et al. 1993; Kessler et al. 1999; Wittchen et al. 2000; Kessler et al. 2001; Kessler and Wittchen 2002; Wittchen 2002). Consequently, comprehensive evaluations of treatment for GAD must include both clinical endpoints (i.e., Hamilton Anxiety Scale-Anxiety [HAM-A]) and assessments of patient-reported QOL and functioning. Moreover, it has been estimated that 92.1% of individuals with GAD also have another lifetime comorbid psychiatric disorder (Ruscio et al. 2007). Anxiety and depression often co-occur, and it has been proposed that a search for one condition should be accompanied by an assessment of the other (Kroenke et al. 2007). The inclusion of patientreported outcomes (PROs) in clinical development programs for GAD treatments will provide useful information for clinicians and their patients about the benefits of treatment on patient functioning and well-being, and the relationship between GAD and depression. The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), in both the long and short form (Q-LES-Q(SF)), is a widely used instrument for measuring QOL and satisfaction. Originally developed for use in clinical trials and among trial participants with a wide variety of mental and medical diseases or disorders (Endicott et al. 1993), it has been shown to offer high internal consistency, validity and reproducibility in non-psychiatric populations and in patients with a range of psychiatric illnesses (Endicott et al. 1993; Ritsner et al. 2005; Rossi et al. 2005; Endicott et al. 2006; Schechter et al. 2007; Mick et al. 2008; Revicki et al. 2008). Thus, the Q-LES-Q(SF) is a PRO measure that has the potential to extend and complement clinical efficacy endpoints and demonstrate the impact of alleviating GAD symptoms on patients’ everyday functioning. To date, few published studies have examined

The Measurement of Health-Related Quality of Life in a Population with Generalized Anxiety Disorder – Findings from the QUEST Study